Larry Goldstein to Hydroxymethylglutaryl-CoA Reductase Inhibitors
This is a "connection" page, showing publications Larry Goldstein has written about Hydroxymethylglutaryl-CoA Reductase Inhibitors.
Connection Strength
7.838
-
Aggressive LDL-C Lowering and the Brain: Impact on Risk for Dementia and Hemorrhagic Stroke: A Scientific Statement From the American Heart Association. Arterioscler Thromb Vasc Biol. 2023 10; 43(10):e404-e442.
Score: 0.693
-
Association of Statin Use With Risk of Stroke Recurrence After Intracerebral Hemorrhage. Neurology. 2023 10 31; 101(18):e1793-e1806.
Score: 0.691
-
Reader response: Association of statin use with spontaneous intracerebral hemorrhage: A cohort study. Neurology. 2019 04 23; 92(17):821-822.
Score: 0.511
-
Adverse Effects of Statins. JAMA. 2017 03 14; 317(10):1079.
Score: 0.441
-
Statins and poststroke intracerebral hemorrhage: Concern but increasing reassurance. Neurology. 2016 04 26; 86(17):1570-1.
Score: 0.413
-
Statin therapy should be discontinued in patients with intracerebral hemorrhage. Stroke. 2013 Jul; 44(7):2058-9.
Score: 0.340
-
Letter by goldstein regarding article, "statins and intracerebral hemorrhage". Circulation. 2012 Jun 12; 125(23):e1015.
Score: 0.317
-
Statins after intracerebral hemorrhage: to treat or not to treat. Arch Neurol. 2011 May; 68(5):565-6.
Score: 0.288
-
The quest for the "Holy Grail" of ischemic stroke cytoprotection: Statins may not be the answer. Neurology. 2009 Dec 15; 73(24):2058-9.
Score: 0.265
-
Statin treatment and stroke outcome in the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial. Stroke. 2009 Nov; 40(11):3526-31.
Score: 0.262
-
Statins and ischemic stroke severity: cytoprotection. Curr Atheroscler Rep. 2009 Jul; 11(4):296-300.
Score: 0.259
-
JUPITER and the world of stroke medicine. Lancet Neurol. 2009 Feb; 8(2):129-31.
Score: 0.252
-
Relative effects of statin therapy on stroke and cardiovascular events in men and women: secondary analysis of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Study. Stroke. 2008 Sep; 39(9):2444-8.
Score: 0.242
-
10 questions about statins and stroke. Neurologist. 2008 Jul; 14(4):262-4.
Score: 0.241
-
Statins for stroke prevention. Curr Atheroscler Rep. 2007 Oct; 9(4):305-11.
Score: 0.229
-
Low LDL cholesterol, statins, and brain hemorrhage: should we worry? Neurology. 2007 Mar 06; 68(10):719-20.
Score: 0.220
-
Statins for secondary stroke prevention in patients without known coronary heart disease: the jury is still out. Cerebrovasc Dis. 2004; 18(1):1-2.
Score: 0.182
-
Association Between Statin Use and Intracerebral Hemorrhage Location: A Nested Case-Control Registry Study. Neurology. 2023 03 07; 100(10):e1048-e1061.
Score: 0.164
-
Association of Long-term Statin Use With the Risk of Intracerebral Hemorrhage: A Danish Nationwide Case-Control Study. Neurology. 2022 Aug 15; 99(7):e711-e719.
Score: 0.161
-
Atorvastatin Reduces First and Subsequent Vascular Events Across Vascular Territories: The SPARCL Trial. J Am Coll Cardiol. 2020 05 05; 75(17):2110-2118.
Score: 0.136
-
Statin Safety and Associated Adverse Events: A Scientific Statement From the American Heart Association. Arterioscler Thromb Vasc Biol. 2019 02; 39(2):e38-e81.
Score: 0.126
-
Statins and the Risk of Intracerebral Hemorrhage in Patients With Previous Ischemic Stroke or Transient Ischemic Attack. Stroke. 2017 12; 48(12):3245-3251.
Score: 0.115
-
Chronic kidney disease and stroke. Adv Chronic Kidney Dis. 2014 Nov; 21(6):500-8.
Score: 0.094
-
Effect of high-dose atorvastatin on renal function in subjects with stroke or transient ischemic attack in the SPARCL trial. Stroke. 2014 Oct; 45(10):2974-82.
Score: 0.092
-
An assessment by the Statin Cognitive Safety Task Force: 2014 update. J Clin Lipidol. 2014 May-Jun; 8(3 Suppl):S5-16.
Score: 0.090
-
Atherogenic dyslipidemia and residual cardiovascular risk in statin-treated patients. Stroke. 2014 May; 45(5):1429-36.
Score: 0.090
-
Modern medical management of acute ischemic stroke. Methodist Debakey Cardiovasc J. 2014 Apr-Jun; 10(2):99-104.
Score: 0.090
-
Advances in stroke: Prevention and health services delivery 2012-2013. Stroke. 2014 Feb; 45(2):371-2.
Score: 0.089
-
Risk of stroke and cardiovascular events after ischemic stroke or transient ischemic attack in patients with type 2 diabetes or metabolic syndrome: secondary analysis of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial. Arch Neurol. 2011 Oct; 68(10):1245-51.
Score: 0.074
-
Advances in prevention and health services delivery 2009. Stroke. 2010 Feb; 41(2):e71-3.
Score: 0.067
-
Atorvastatin reduces the risk of cardiovascular events in patients with carotid atherosclerosis: a secondary analysis of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial. Stroke. 2008 Dec; 39(12):3297-302.
Score: 0.062
-
Baseline blood pressure, low- and high-density lipoproteins, and triglycerides and the risk of vascular events in the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial. Atherosclerosis. 2009 Jun; 204(2):515-20.
Score: 0.061
-
Effect of atorvastatin in elderly patients with a recent stroke or transient ischemic attack. Neurology. 2009 Feb 24; 72(8):688-94.
Score: 0.061
-
Update to the AHA/ASA recommendations for the prevention of stroke in patients with stroke and transient ischemic attack. Stroke. 2008 May; 39(5):1647-52.
Score: 0.059
-
Efficacy of drug therapy in the secondary prevention of cardiovascular disease and stroke. Am J Cardiol. 2007 Mar 27; 99(6C):1E-35E.
Score: 0.055
-
High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med. 2006 08 10; 355(6):549-59.
Score: 0.053
-
Statin use and sex-specific stroke outcomes in patients with vascular disease. Stroke. 2006 Jun; 37(6):1427-31.
Score: 0.052
-
Statin use and stroke outcomes in the Heart and Estrogen-Progestin Replacement Study (HERS). Neurology. 2004 Mar 23; 62(6):968-70.
Score: 0.045
-
Prevention and health services delivery. Stroke. 2004 Feb; 35(2):401-3.
Score: 0.044
-
Prevention and health services delivery. Stroke. 2003 Feb; 34(2):367-9.
Score: 0.041
-
Design and baseline characteristics of the stroke prevention by aggressive reduction in cholesterol levels (SPARCL) study. Cerebrovasc Dis. 2003; 16(4):389-95.
Score: 0.041
-
Association of Osteopontin, Neopterin, and Myeloperoxidase With Stroke Risk in Patients With Prior Stroke or Transient Ischemic Attacks: Results of an Analysis of 13 Biomarkers From the Stroke Prevention by Aggressive Reduction in Cholesterol Levels Trial. Stroke. 2017 12; 48(12):3223-3231.
Score: 0.029